Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux

Leukemia Research

Volumn 32, Issue 3, 2008, Pages 465-473

  Chau, MyDoanh ^a   Christensen, Jennifer L ^a   Ajami, Alfred M ^a   Capizzi, Robert L ^a  

^a Xanthus Pharmaceuticals Inc   (United States)

Author keywords

Acute leukemia; Amonafide; Multidrug resistance; P glycoprotein; Topoisomerase II inhibitor

Indexed keywords

AMONAFIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DIGOXIN; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IDARUBICIN; MIDOSTAURIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENCY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LC 50; LEUKEMIA CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; ENZYME INHIBITORS; HUMANS; IMIDES; ISOQUINOLINES; MICE; NAPHTHALIMIDES; P-GLYCOPROTEIN;

EID: 39749089553     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.07.017     Document Type: Article

References (42)

1. Schiffer C.A., and Stone R. Acute myeloid leukemia in adults mast cell leukemia and other mast cell neoplasms. In: Kufe D.W., Bast R.C., Hait W., Hong W.K., Pollock R.E., Weichselbaum R.R., Holland J.F., and Frei E. (Eds). Cancer Medicine. 7th ed. (2006), Hamilton, Ont., BC Decker 1739-1760
2. Mayer R.J., Davis R.B., Schiffer C.A., Berg D.T., Powell B.L., Schulman P., et al. Intensive postremission chemotherapy in adults with acute myeloid leukaemia. Cancer and Leukemia Group B. N Engl J Med 331 (1994) 896-903
3. Appelbaum F.R., Gundacker H., Head D.R., Slovak M.L., Willman C.L., Godwin J.E., et al. Age and acute myeloid leukemia. Blood 107 (2006) 3481-3485
4. Appelbaum F.R., Rosenblum D., Arceci R.J., Carroll W.L., Breitfeld P.P., Forman S.J., et al. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood 109 (2007) 1810-1816
5. Baer M.R., George S.L., Dodge R.K., O'Loughlin K.L., Minderman H., Caligiuri M.A., et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100 (2002) 1224-1232
6. Leith C.P., Kopecky K.J., Godwin J., McConnell T., Slovak M.L., Chen I.M., et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89 (1997) 3323-3329
7. Gottesman M.M., and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62 (1993) 385-427
8. Litman T., Druley T.E., Stein W.D., and Bates S.E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58 (2001) 931-959
9. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., and Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5 (2006) 219-234
10. Leith C.P., Chen I.M., Kopecky K.J., Appelbaum F.R., Head D.R., Godwin J.E., et al. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. Blood 86 (1995) 2329-2342
11. Baer M.R. Clinical significance of multidrug resistance in AML: current insights. Clin Adv Hematol Oncol 3 (2005) 910-912
12. Greenberg P.L., Lee S.J., Advani R., Tallman M.S., Sikic B.I., Letendre L., et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 22 (2004) 1078-1086
13. Dorr R., Karanes C., Spier C., Grogan T., Greer J., Moore J., et al. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J Clin Oncol 19 (2001) 1589-1599
14. Kolitz J.E., George S.L., Dodge R.K., Hurd D.D., Powell B.L., Allen S.L., et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 22 (2004) 4290-4301
15. van der Holt B., Lowenberg B., Burnett A.K., Knauf W.U., Shepherd J., Piccaluga P.P., et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106 (2005) 2646-2654
16. Cripe L.D., Li X., Litzow M., Paietta E., Rowe J.M., Luger S., et al. A randomized, placebo-controlled, double blind trial of the MDR modulator, zosuquidar, during conventional induction and post-remission therapy for Pts >60 years of age with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): ECOG 3999. Blood 108 (2006) 129a
17. Stone R. Targeted agents in AML: much more to do. Best Prac Res Clin Haematol 20 (2007) 39-48
18. Hsiang Y.H., Jiang J.B., and Liu L.F. Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs. Mol Pharmacol 36 (1989) 371-376
19. Sami S.M., Dorr R.T., Alberts D.S., Solyom A.M., and Remers W.A. 2-[2′-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10 and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships. J Med Chem 39 (1996) 4978-4987
20. Sami S.M., Dorr R.T., Solyom A.M., Alberts D.S., Iyengar B.S., and Remers W.A. Six- and 7-substituted 2-[2′-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships. J Med Chem 39 (1996) 1609-1618
21. O'Brien S., Benvenuto J.A., Estey E., Beran M., Felder T.B., and Keating M. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. Cancer Res 51 (1991) 935-938
22. Allen S.L., Budman D., and Kreis W. Phase 1 trial of amonafide for poor prognosis acute leukemias and blast crisis of chronic myelogenous leukemia. Blood 78 Suppl. 1 (1991) 31a
23. Allen S.L., Budman D., Fusco D., Kreis W., Schulman P., and Weiselberg L. Phase 1 trial of amonafide for refractory, relapsed, or secondary acute leukemias and blast crisis chronic myelogenous leukemia. Proc Am Soc Clin Oncol 11 (1992) 276
24. Allen S.L., Budman D.R., Kreis W., Fusco D., Schulman P., Weiselberg L., et al. Phase 1 trial of amonafide (AM) for poor prognosis acute leukemias. Leuk Res 15 Suppl. 1 (1991) 32
25. Allen S.L., Budman D., Fusco D., Kolitz J., Kreis W., Schulman P., et al. Phase 1 trial of amonafide and cytosine arabinoside for poor risk acute leukemias. Proc Am Assoc Cancer Res 35 (1994) 225
26. Polli J.W., Wring S.A., Humphreys J.E., Huang L., Morgan J.B., Webster L.O., et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299 (2001) 620-628
27. Qadir M., O'Loughlin K.L., Fricke S.M., Williamson N.A., Greco W.R., Minderman H., et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 11 (2005) 2320-2326
28. Ganeshaguru K., Wickremasinghe R.G., Jones D.T., Gordon M., Hart S.M., Virchis A.E., et al. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica 87 (2002) 167-176
29. Leith C.P., Kopecky K.J., Chen I.M., Eijdems L., Slovak M.L., McConnell T.S., et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94 (1999) 1086-1099
30. Young I.T. Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem 25 (1977) 935-941
31. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
32. Boesch D., Muller K., Pourtier-Manzanedo A., and Loor F. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp Cell Res 196 (1991) 26-32
33. Frey T., Yue S., and Haugland R.P. Dyes providing increased sensitivity in flow-cytometric dye-efflux assays for multidrug resistance. Cytometry 20 (1995) 218-227
34. Radel S., Fredericks W., Mayhew E., and Baker R. P-glycoprotein expression and modulation of cell-membrane morphology in adriamycin-resistant P388 leukemia cells. Cancer Chemother Pharmacol 25 (1990) 241-246
35. Zhang L., Strong J.M., Qiu W., Lesko L.J., and Huang S.M. Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm 3 (2006) 62-69
36. Weinstein K., Kardos P., Strab R., and Hidalgo I. Cultured epithelial cell assays used to estimate intestinal absorption potential. Pharmaceutical Profiling in Drug Discovery for Lead Selection (2004), AAPS Press, Arlington, VA p. 217-234
37. Mahadevan D. Will MDR-1/P-gp modulators provide clinical benefit in hematologic malignancies?. Leuk Res 30 (2006) 1077-1078
38. Brana M.F., and Ramos A. Naphthalimides as anti-cancer agents: synthesis and biological activity. Curr Med Chem Anticancer Agents 1 (2001) 237-255
39. Wang H., Mao Y., Zhou N., Hu T., Hsieh T.S., and Liu L.F. ATP-bound topoisomerase II as a target for antitumor drugs. J Biol Chem 276 (2001) 15990-15995
40. Allen S.L., Kolitz J.E., Lundberg A., Champagne M., Devost S., Dubon R., et al. Phase I study of amonafide + cytosine arbinoside (AraC) in patients with poor risk acute myeloid leukemia (AML). Proc Am Soc Clin Oncol 23 (2005) 585s
41. Erba H.P., Rizzieri D.A., O'Donnell M.R., Lundberg A.S., Ajami A.M., Rampersad A.D., et al. Amonafide and ara-C treatment for secondary acute myeloid leukemia (sAML). Proc Am Soc Clin Oncol 25 (2007) 373s
42. Godwin J.E., Kopecky K.J., Head D.R., Willman C.L., Leith C.P., Hynes H.E., et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study (9031). Blood 91 (1998) 3607-3615